Cover Image
市場調查報告書

肺部藥物遞輸系統:各種技術和全球市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

出版商 BCC Research 商品編碼 224407
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
Back to Top
肺部藥物遞輸系統:各種技術和全球市場 Pulmonary Drug Delivery Systems: Technologies and Global Markets
出版日期: 2018年04月24日 內容資訊: 英文 121 Pages
簡介

全球肺部藥物遞輸系統的市場在預測期間內預計以4.3%的年複合成長率發展,從2017年的381億美元,成長到2022年的470億美元的規模。

本報告提供肺部藥物遞輸系統的技術及市場調查,市場定義和概要,肺部疾病和治療藥,市場成長的各種影響因素及市場機會分析,相關法律,各系統區分、疾病區分、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 市場動態、技術背景

  • 市場定義、概要
    • 作用機制
    • 優點
    • 規定、課題
  • 肺部疾病和治療藥
  • 市場成長的促進因素、趨勢
  • 市場成長的阻礙因素
  • 市場機會
  • 法律制度

第4章 市場分析、預測:各系統種類

  • 吸入法:概要
  • 主要的呼吸系統產品
  • 乾粉吸入劑 (DPI)
    • 概要
    • 已上市產品
    • 市場規模、預測
  • 定量噴霧吸入器 (MDI)
    • 概要
    • 已上市產品
    • 市場規模、預測
  • 噴霧器
    • 概要
    • 已上市產品概要:各製造業
    • 市場規模、預測

第5章 所利用的肺部藥物遞輸系統系統

  • 吸入給藥劑
    • 類固醇
    • 支氣管擴張劑

第6章 市場分析、預測:各疾病種類

  • 簡介
  • 氣喘
    • 氣喘發作
    • 氣喘與肥胖
    • 死亡率
    • 疾病的分類
    • 診斷
    • 治療、治療藥
    • 市場規模、預測
  • 慢性阻塞性肺病 (COPD)
    • 診斷
    • 治療、治療藥
    • 市場規模、預測
  • 其他
    • 市場規模、預測

第7章 市場分析、預測:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他
  • 中東、非洲
  • 南美

第8章 競爭環境、主要的部署

  • 主要企業、市場結構分析
  • 專利分析
    • 主要專利
    • 開發平台分析
  • 主要的部署
    • M&A
    • 創新的產品的開發、新產品的投入
    • 協定、聯盟、合作

第9章 企業簡介

附錄

關於BCC Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC094C

The global pulmonary drug delivery systems market totaled $38.1 billion in 2017 and is estimated to reach $47.0 billion by 2022, growing at a compound annual growth rate (CAGR) of 4.3% for the period of 2017-2022.

Report Includes

  • 74 tables
  • A detailed overview and analysis of the global markets for pulmonary drug delivery systems
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
  • A look at the regulatory environment, which has been a driving force in the healthcare industry
  • Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
  • Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd

Report Scope

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.

In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.

A discussion of the major players is included in the Competitive Landscape section. The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.

Analyst Credentials

Led by Research Head Karthik Arun, the BCC Research staff is composed of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration, surgery and other subject areas.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Dynamics and Technology Background

  • Market Definition and Overview
    • Mechanism of Action
    • Advantages
    • Limitations/Challenges
  • Pulmonary Conditions and Therapies
    • Introduction to the Respiratory System
  • Market Driving Factors and Trends
    • Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products
    • Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices
    • Rising Incidence of Asthma and COPD in Developing and Developed Regions
  • Market Restraints
    • Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products
  • Market Opportunities
    • Introduction of Smart Nebulizers
  • Regulation and Legislation
    • United States

Chapter 4: Market Breakdown by Pulmonary Drug Delivery Systems

  • Overview of Inhalation Techniques
  • Leading Respiratory Products
  • Dry Powder Inhalers (DPIs)
    • Overview
    • Marketed Products
    • Market Size and Forecast
  • Metered Dose Inhalers (MDI's)
    • Overview
    • Marketed Products
    • Market Size and Forecast
  • Nebulizers
    • Overview
    • Marketed Products Overview by Manufacturer
    • Market Size and Forecast

Chapter 5: Pulmonary Drug Delivery Systems in Use

  • Therapeutic Agents Administered via Inhalation
    • Steroids
    • Bronchodilators

Chapter 6: Market Breakdown by Disease Area

  • Introduction
  • Asthma
    • Asthma Attack
    • Asthma and Obesity
    • Mortality
    • Disease Classification
    • Diagnosis
    • Treatment and Therapies
    • Market Size and Forecasts
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Diagnosis
    • Treatment and Therapies
    • Market Size and Forecast
  • Other Diseases
    • Market Size and Forecast

Chapter 7: Market Breakdown by Region

  • North America
    • U.S.A.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
  • South America

Chapter 8: Competitive Landscape and Key Developments

  • Leading Players and Market Structure Analysis
  • Patent Analysis
    • List of Key Patents
    • Pipeline Analysis
  • Key Developments
    • Mergers and Acquisitions
    • Development of Innovative Products/Novel Product Launches
    • Agreements, Collaborations and Partnerships

Chapter 9: Company Profiles

Appendix

  • Acronyms

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table A Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2022 ($ Millions)
  • Summary Table B Global Market for Pulmonary Drug Delivery Systems, by Region Through 2022 ($ Millions)
  • Table 1 Global Asthma and COPD Snapshot, 1990-2015
  • Table 2 Key Products Going off-Patent, 2016-2021
  • Table 3 Inhaler Device Characteristics Snapshot
  • Table 4 Global Market for Pulmonary Drug, by Delivery System, Through 2022 ($ Millions)
  • Table 5 Global Respiratory Product Sales, 2014-2016 ($ Millions)
  • Table 6 Capsule Based Inhaler Devices
  • Table 7 Blister Based Inhaler Devices
  • Table 8 Reservoir/Cartridge Based Inhaler Devices
  • Table 9 Global Dry Powder Inhaler Market, by Region, Through 2022 ($ Millions)
  • Table 10 MDIs, HFA Propellant
  • Table 11 MDIs, Anti-Inflammatory Medicine
  • Table 12 MDIs, Combination Medicine
  • Table 13 Commonly Used MDIs
  • Table 14 Global MDI Market, by Region, Through 2022 ($ Millions)
  • Table 15 Comparison of Nebulizers
  • Table 16 Marketed Nebulizers by Manufacturer
  • Table 17 Global Nebulizer Market, by Region, Through 2022 ($ Millions)
  • Table 18 Inhaled Steroids
  • Table 19 Inhaled Corticosteroids
  • Table 20 Inhaled Corticosteroids, Combination Inhalers
  • Table 21 Short-Acting Inhaled Beta-Agonist Bronchodilators
  • Table 22 Short-Acting Inhaled Muscarinic Antagonist Combination Bronchodilators
  • Table 23 Long-Acting Inhaled LABAs (Long-Acting Beta2 Agonists)
  • Table 24 Long-Acting Inhaled LAMAs (Long-Acting Muscarinic Antagonists)
  • Table 25 LABA and LAMA Combinations
  • Table 26 Top Asthma/COPD Product Sales, 2015-2017 ($ Millions)
  • Table 27 U.S. Asthma Mortality, 2015
  • Table 28 U.S. Asthma Prevalence, 2015
  • Table 29 Global Asthma Market, by Region Through 2022 ($ Millions)
  • Table 30 Global COPD Market, by Region, Through 2022 ($ Millions)
  • Table 31 Global Market for Other Pulmonary Diseases, by Region, Through 2022 ($ Millions)
  • Table 32 Canadian Disease Prevalence, Asthma and COPD, 2012-2014 (Number of Persons)
  • Table 33 European Self-Reported Asthma, 2014 (% of Population)
  • Table 34 European Self-Reported COPD, 2014 (% of Population)
  • Table 35 Leading Causes of Death in Australia, 2011-2016
  • Table 36 Patent Review, Inhaler, 2013-2018
  • Table 37 Sunovion Pharmaceuticals, Inc., SUN-101/ eFlow (Glycopyrrolate), 2017
  • Table 38 AstraZeneca plc, (Pearl Therapeutics), Pulmonary Products Pipeline
  • Table 39 Teva Pharmaceuticals Industries Ltd., Pulmonary Products Pipeline
  • Table 40 Vectura Group plc, Pulmonary Products Pipeline
  • Table 41 GlaxoSmithKline plc, Pulmonary Products Pipeline
  • Table 42 3M Pharmaceuticals, Inc., Marketed Products, 2016
  • Table 43 3M Pharmaceuticals, Inc., Net Revenue, 2015-2017 ($ Millions)
  • Table 44 AstraZeneca plc, Marketed Products, 2016
  • Table 45 AstraZeneca plc., Key Developments, 2016
  • Table 46 AstraZeneca plc, Net Revenue, 2014-2016 ($ Millions)
  • Table 47 Boehringer Ingelheim GmbH, Marketed Product, 2016
  • Table 48 Boehringer Ingelheim GmbH, Net Revenue, 2014-2016 ($ Millions)
  • Table 49 Cipla, Inc., Marketed Products, 2016
  • Table 50 Cipla, Inc., Net Revenue, 2015-2017 ($ Millions)
  • Table 51 Dr. Reddy's Laboratories Ltd., Marketed Products, 2016
  • Table 52 Dr. Reddy's Laboratories Ltd., Net Revenue, 2015-2017 ($ Millions)
  • Table 53 GlaxoSmithKline plc, Marketed Products, 2016
  • Table 54 GlaxoSmithKline plc, Net Revenue, 2014-2016 ($ Millions)
  • Table 55 Koninklijke Philips N.V., Marketed Products, 2016
  • Table 56 Lupin Limited, Key Developments
  • Table 57 Lupin Limited, Net Revenue, 2015-2017 ($ Millions)
  • Table 58 Mylan N.V., Marketed Products, 2016
  • Table 59 Mylan N.V., Key Developments, 2016
  • Table 60 Mylan N.V., Net Revenue, 2015-2017 ($ Millions)
  • Table 61 Novartis AG, Marketed Products, 2016
  • Table 62 Novartis AG, Key Developments, 2016
  • Table 63 Novartis AG, Net Revenue, 2014-2016 ($ Millions)
  • Table 64 Omron Corp., Marketed Products, 2016
  • Table 65 Omron Corp., Net Revenue, 2014-2016 ($ Millions)
  • Table 66 Pfizer, Inc., Marketed Products, 2016
  • Table 67 Pfizer, Inc., Net Revenue, 2014-2016 ($ Millions)
  • Table 68 Teva Pharmaceutical Industries Ltd., Marketed Products, 2016
  • Table 69 Teva Pharmaceutical Industries Ltd., Net Revenue, 2014-2016 ($ Millions)
  • Table 70 Vectura Group plc, Marketed Products, 2016
  • Table 71 Vectura Group plc, Net Revenue, 2015-2017 ($ Millions)
  • Table 72 Abbreviations Used in Pulmonary Drug Delivery Systems

List of Figures

  • Summary Figure A Global Market for Pulmonary Drug Delivery Systems, by Type, 2016-2022 ($ Millions)
  • Summary Figure B Global Market for Pulmonary Drug Delivery Systems, by Region, 2016-2022 ($ Millions)
  • Figure 1 Estimation of Daily Smoking Patterns, by Region, 2015 (Millions)
  • Figure 2 Global Market for Pulmonary Drug, by Delivery System, 2016-2022 ($ Millions)
  • Figure 3 Global Dry Powder Inhaler Market, by Region, 2016-2022 ($ Millions)
  • Figure 4 Global MDI Market, by Region, 2016-2022 ($ Millions)
  • Figure 5 Global Nebulizer Market, by Region, 2016-2022 ($ Millions)
  • Figure 6 Non-communicable Disease Mortality Share, by Cause of Death, 2015 (%)
  • Figure 7 Global Asthma Market, 2016-2022 ($ Millions)
  • Figure 8 Global Asthma Market, by Region, 2016-2022 ($ Millions)
  • Figure 9 Top 10 Leading Causes of Death in the World, 2015 (Millions)
  • Figure 10 Global COPD Market, 2016-2022 ($ Millions)
  • Figure 11 Global COPD Market, by Region, 2016-2022 ($ Millions)
  • Figure 12 Global Market for Other Pulmonary Disease, 2016-2022 ($ Millions)
  • Figure 13 Global Market for Other Pulmonary Disease, by Region, 2016-2022 ($ Millions)
  • Figure 14 North American Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 15 Impact of Asthma in North America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 16 Impact of COPD in North America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 17 Mexican Population Health Issues, Proportional Mortality, 2014 (%)
  • Figure 18 Impact of Asthma in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 19 Impact of COPD in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 20 European Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 21 United Kingdom Mortality Rates in Males, 2015 (%)
  • Figure 22 United Kingdom Mortality Rate in Females, 2015 (%)
  • Figure 23 Leading Causes of Death in Italy in Percent Change, 2005-2016
  • Figure 24 Spain Mortality Rate in Women, 2014 (%)
  • Figure 25 Spain Mortality Rate in Men, 2014 (%)
  • Figure 26 Leading Causes of Death in Europe, 2015
  • Figure 27 Asia Pacific Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 28 Impact of Asthma in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 29 Impact of COPD in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 30 Impact of Asthma in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 31 Impact of COPD in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People) 81
  • Figure 32 Middle East and African Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 33 Impact of Asthma in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 34 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 35 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 36 South American Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 37 3M Pharmaceuticals, Inc., Revenue Share by Region, 2016 (%)
  • Figure 38 3M Pharmaceuticals, Inc., Revenue Share by Business Segment, 2016 (%)
  • Figure 39 AstraZeneca plc, Revenue Share, by Region, 2016 (%)
  • Figure 40 AstraZeneca plc, Revenue Share, by Business Segment, 2016 (%)
  • Figure 41 Boehringer Ingelheim GmbH, Research and Development Expenditure, 2014-2016 ($ Millions)
  • Figure 42 Boehringer Ingelheim GmbH, Revenue Share by Region, 2016 (%)
  • Figure 43 Boehringer Ingelheim GmbH, Revenue Share, by Business Segment, 2016 (%)
  • Figure 44 Cipla, Inc. Research and Development Expenditure, 2014-2017 (%)
  • Figure 45 Cipla, Inc., Revenue Share, by Region, 2017 (%)
  • Figure 46 Cipla, Inc., Revenue Share, by Business Segment, 2017 (%)
  • Figure 47 Dr. Reddy's Laboratories Ltd., Revenue Share, by Region, 2017 (%)
  • Figure 48 Dr. Reddy's Laboratories Ltd., Revenue Share, by Business Segment, 2017 (%)
  • Figure 49 GlaxoSmithKline plc, Pharmaceuticals Revenue Share, by Therapy Areas, 2016 (%) 120
  • Figure 50 GlaxoSmithKline plc, Revenue Share, by Region, 2016 (%)
  • Figure 51 Mylan N.V., Revenue Share by Therapy Areas, 2016 (%)
  • Figure 52 Mylan N.V., Revenue Share, by Region, 2016 (%)
  • Figure 53 Novartis AG, Revenue Share, by Region, 2016 (%)
  • Figure 54 Novartis AG, Revenue Share, by Business Segment, 2016 (%)
  • Figure 55 Omron Corp., Revenue Share, by Healthcare Business Segment (HCB), 2017 (%)
  • Figure 56 Omron Corp., Revenue Share, by Region, 2017 (%)
  • Figure 57 Pfizer, Inc., Revenue Share, by Region, 2016 (%)
  • Figure 58 Pfizer, Inc., Revenue Share, by Business Segment, 2016 (%)
  • Figure 59 Teva Pharmaceutical Industries Ltd., Revenue Share, by Region, 2017 (%)
  • Figure 60 Teva Pharmaceutical Industries Ltd., Revenue Share, by Business Segment, 2016 (%) .
  • Figure 61 Vectura Group plc, Research and Development Expenditure, 2014-2016 ($ Millions)
  • Figure 62 Vectura Group plc, Revenue Share, by Region, 2017 (%)
Back to Top